Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders
Vaccines will be introduced in contexts where TPT already exists. Exploration of possible study designs, expected effectiveness, feasibility of integrated approaches is key.
we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.
We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.